These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 25503977)

  • 1. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.
    Schwameis M; Schörgenhofer C; Assinger A; Steiner MM; Jilma B
    Thromb Haemost; 2015 Apr; 113(4):708-18. PubMed ID: 25503977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases.
    Franchini M; Montagnana M; Targher G; Lippi G
    Semin Thromb Hemost; 2007 Nov; 33(8):787-97. PubMed ID: 18175284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
    Kato S; Fujimura Y
    Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13.
    Chapman K; Seldon M; Richards R
    Semin Thromb Hemost; 2012 Feb; 38(1):47-54. PubMed ID: 22314603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombotic thrombocytopenic purpura and anti-thrombotic therapy targeted to von Willebrand factor.
    Zhou Z; Dong JF
    Curr Vasc Pharmacol; 2012 Nov; 10(6):762-6. PubMed ID: 22022775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases.
    Habe K; Wada H; Ito-Habe N; Hatada T; Matsumoto T; Ohishi K; Maruyama K; Imai H; Mizutani H; Nobori T
    Thromb Res; 2012 May; 129(5):598-602. PubMed ID: 22070827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies.
    Crawley JT; Scully MA
    Hematology Am Soc Hematol Educ Program; 2013; 2013():292-9. PubMed ID: 24319194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
    Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
    Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired thrombotic thrombocytopenic purpura: new therapeutic options and their optimal use.
    Cataland SR; Wu HM
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S223-9. PubMed ID: 26149028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential therapeutic benefit of targeting ADAMTS13 activity.
    Eerenberg ES; Levi M
    Semin Thromb Hemost; 2014 Feb; 40(1):28-33. PubMed ID: 24338607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Overview of Laboratory Testing for ADAMTS13.
    Favaloro EJ; Pasalic L
    Methods Mol Biol; 2023; 2663():481-486. PubMed ID: 37204731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in thrombotic thrombocytopenic purpura.
    Sadler JE; Moake JL; Miyata T; George JN
    Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.
    Budde U; Schneppenheim R
    Hamostaseologie; 2014; 34(3):215-25. PubMed ID: 25010251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated and Rapid ADAMTS13 Testing Using Chemiluminescence: Utility for Identification or Exclusion of TTP and Beyond.
    Favaloro EJ; Chapman K; Mohammed S; Vong R; Pasalic L
    Methods Mol Biol; 2023; 2663():487-504. PubMed ID: 37204732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
    Shah N; Rutherford C; Matevosyan K; Shen YM; Sarode R
    Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. von Willebrand factor and thrombotic thrombocytopenic purpura.
    Raife TJ; Montgomery RR
    Curr Opin Hematol; 2000 Sep; 7(5):278-83. PubMed ID: 10961577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura.
    Zhou Z; Nguyen TC; Guchhait P; Dong JF
    Semin Thromb Hemost; 2010 Feb; 36(1):71-81. PubMed ID: 20391298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure.
    Ono T; Mimuro J; Madoiwa S; Soejima K; Kashiwakura Y; Ishiwata A; Takano K; Ohmori T; Sakata Y
    Blood; 2006 Jan; 107(2):528-34. PubMed ID: 16189276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
    Tersteeg C; Schiviz A; De Meyer SF; Plaimauer B; Scheiflinger F; Rottensteiner H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2336-42. PubMed ID: 26338302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.
    Manea M; Karpman D
    Pediatr Nephrol; 2009 Mar; 24(3):447-58. PubMed ID: 18807073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.